{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:35:38Z","timestamp":1793486138846,"version":"4.5.0"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Compared with antipsychotics, the relationship between antidepressant blood (plasma or serum) concentrations and target engagement is less well-established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We have discussed the literature on the relationship between plasma concentrations of antidepressant drugs and their target occupancy. Antidepressants reviewed in this work are citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, duloxetine, milnacipran, tricyclic antidepressants (amitriptyline, nortriptyline, and clomipramine), bupropion, tranylcypromine, moclobemide, and vortioxetine. Four electronic databases were systematically searched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We included 32 articles published 1996\u20132022. A strong relationship between serotonin transporter (SERT) occupancy and drug concentration is well established for selective serotonin reuptake inhibitors. Lower limits of recommended therapeutic reference ranges largely corroborate with the findings from positron emission tomography studies (80% SERT occupancy). Only a few novel studies have investigated alternative targets, that is, norepinephrine transporters (NETs), dopamine transporters (DATs), or monoamine oxidase A (MAO-A). For certain classes of drugs, positron emission tomography study data are inconclusive. Low DAT occupancy after bupropion treatment speculates its discussed mechanism of action. For MAO inhibitors, a correlation between drug concentration and MAO-A occupancy could not be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Neuroimaging studies are critical in TDM-guided therapy for certain antidepressants, whereas for bupropion and MAO inhibitors, the available evidence offers no further insight. Evidence for selective serotonin reuptake inhibitors is strong and justifies a titration toward suggested ranges. For SNRIs, duloxetine, and venlafaxine, NETs are sufficiently occupied, well above the SERT efficacy threshold. For these drugs, a titration toward higher concentrations (within the recommended range) should be considered in case of no response at lower concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001142","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T03:09:34Z","timestamp":1706584174000},"page":"155-169","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-0189","authenticated-orcid":false,"given":"Xenia M.","family":"Hart","sequence":"first","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"},{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Spangemacher","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"},{"name":"Department of Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Defert","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","article-title":"Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging","volume":"44","author":"Gr\u00fcnder","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"972141","DOI":"10.3389\/fpsyt.2022.972141","article-title":"Systematic review and meta-analysis on the therapeutic reference range for escitalopram: blood concentrations, clinical effects and serotonin transporter occupancy","volume":"13","author":"Eichentopf","year":"2022","journal-title":"Front Psychiatry"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants","volume":"22","author":"Eap","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","article-title":"The serotonin theory of depression: a systematic umbrella review of the evidence","volume":"28","author":"Moncrieff","year":"2022","journal-title":"Mol Psychiatry"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1017\/S1461145713001521","article-title":"Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2","volume":"17","author":"Takano","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-011-2212-9","article-title":"NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo","volume":"216","author":"Takano","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R8-20250603","article-title":"Update lessons from positron emission tomography imaging Part I: a systematic critical review on therapeutic plasma concentrations of antipsychotics","author":"Hart","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"832209","DOI":"10.3389\/fpsyt.2022.832209","article-title":"Molecular imaging of dopamine partial agonists in humans: implications for clinical practice","volume":"13","author":"Hart","year":"2022","journal-title":"Front Psychiatry"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1017\/S1461145711001945","article-title":"Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder","volume":"15","author":"Lundberg","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1017\/S1461145706007486","article-title":"PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram","volume":"10","author":"Lundberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00213-007-0806-z","article-title":"Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography","volume":"193","author":"Voineskos","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"108447","DOI":"10.1016\/j.neuropharm.2021.108447","article-title":"Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression","volume":"194","author":"Smith","year":"2021","journal-title":"Neuropharmacology"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-006-0486-0","article-title":"In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram","volume":"188","author":"Klein","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00213-006-0666-y","article-title":"Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study","volume":"191","author":"Klein","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.euroneuro.2014.12.010","article-title":"Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: a [123I]\u03b2-CIT SPECT study","volume":"25","author":"Rominger","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/biom10060880","article-title":"The effect of escitalopram on central serotonergic and dopaminergic systems in patients with cervical dystonia, and its relationship with clinical treatment effects: a double-blind placebo-controlled trial","volume":"10","author":"Zoons","year":"2020","journal-title":"Biomolecules"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.neuroimage.2012.07.023","article-title":"Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas","volume":"63","author":"Lanzenberger","year":"2012","journal-title":"Neuroimage"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","article-title":"Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET","volume":"88","author":"Baldinger","year":"2014","journal-title":"Neuroimage"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pscychresns.2016.03.006","article-title":"Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: a positron emission tomography study with [(11)C]DASB","volume":"251","author":"Arakawa","year":"2016","journal-title":"Psychiatry Res Neuroimaging"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40262-016-0444-x","article-title":"Regional differences in serotonin transporter occupancy by escitalopram: an [(11)C]DASB PK-PD study","volume":"56","author":"Kim","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41398-021-01682-3","article-title":"Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial","volume":"11","author":"Hjorth","year":"2021","journal-title":"Transl Psychiatry"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41398-022-02187-3","article-title":"Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy","volume":"12","author":"Hjorth","year":"2022","journal-title":"Transl Psychiatry"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/jamapsychiatry.2015.0125","article-title":"Serotonin synthesis and reuptake in social anxiety disorder: a positron emission tomography study","volume":"72","author":"Frick","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.115.175794","article-title":"Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial","volume":"209","author":"Gingnell","year":"2016","journal-title":"Br J Psychiatry"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41380-019-0618-7","article-title":"Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study","volume":"26","author":"Hjorth","year":"2021","journal-title":"Mol Psychiatry"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archpsyc.60.4.386","article-title":"High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography","volume":"60","author":"Suhara","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.jcp.0000203201.34323.d3","article-title":"Time course of in vivo 5-HTT transporter occupancy by fluvoxamine","volume":"26","author":"Takano","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1022410306577","article-title":"Antidepressant response and fluvoxamine plasma concentrations: a pilot study","volume":"25","author":"Schwarzenbach","year":"2003","journal-title":"Pharm World Sci"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0924-977X(93)90290-3","article-title":"Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects","volume":"3","author":"Kasper","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/JCP.0b013e3181730850","article-title":"Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression","volume":"28","author":"Suzuki","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"2 pt 1","key":"R34-20250603","doi-asserted-by":"crossref","first-page":"C196","DOI":"10.1152\/ajpcell.1990.259.2.C196","article-title":"High-affinity paroxetine binding to the human placental serotonin transporter","volume":"259","author":"Cool","year":"1990","journal-title":"Am J Physiol."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pscychresns.2013.12.003","article-title":"Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder","volume":"221","author":"Ruhe","year":"2014","journal-title":"Psychiatry Res"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YPG.0000000000000244","article-title":"Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder","volume":"30","author":"Simoons","year":"2020","journal-title":"Psychiatr Genet"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/FTD.0000000000000036","article-title":"Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders","volume":"36","author":"Tomita","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.biopsych.2005.08.010","article-title":"Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography","volume":"59","author":"Parsey","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"e22021","DOI":"10.1002\/syn.22021","article-title":"An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine","volume":"72","author":"Frankle","year":"2018","journal-title":"Synapse"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ijnp\/pyz003","article-title":"Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a PET study using [18F]FMeNER-D2","volume":"22","author":"Arakawa","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","article-title":"Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review","volume":"255","author":"Adli","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00213-005-0304-0","article-title":"A dose-finding study of duloxetine based on serotonin transporter occupancy","volume":"185","author":"Takano","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/jcbfm.2010.175","article-title":"Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy","volume":"31","author":"Abanades","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/ijnp\/pyx069","article-title":"Occupancy of norepinephrine transporter by duloxetine in human brains measured by positron emission tomography with (S,S)-[18F]FMeNER-D2","volume":"20","author":"Moriguchi","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/S1461145712001009","article-title":"Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2)","volume":"16","author":"Nogami","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"suppl 4","key":"R46-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00004850-199609004-00005","article-title":"Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results","volume":"11","author":"Kasper","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hup.484","article-title":"Milnacipran plasma levels and antidepressant response in Japanese major depressive patients","volume":"18","author":"Higuchi","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00213-012-2901-z","article-title":"SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study","volume":"226","author":"Takano","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00213-010-1824-9","article-title":"Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2","volume":"210","author":"Sekine","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00213-002-1166-3","article-title":"Bupropion occupancy of the dopamine transporter is low during clinical treatment","volume":"163","author":"Meyer","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0006-3223(02)01834-6","article-title":"In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography","volume":"54","author":"Learned-Coughlin","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2005.08.016","article-title":"Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study","volume":"89","author":"Argyel\u00e1n","year":"2005","journal-title":"J Affect Disord."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"14065","DOI":"10.1073\/pnas.93.24.14065","article-title":"Brain monoamine oxidase A inhibition in cigarette smokers","volume":"93","author":"Fowler","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.jcbfm.9600197","article-title":"Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain","volume":"26","author":"Ginovart","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1503\/jpn.100117","article-title":"Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study","volume":"36","author":"Sacher","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"pyv078","DOI":"10.1093\/ijnp\/pyv078","article-title":"Monoamine oxidase-A occupancy by moclobemide and phenelzine: implications for the development of monoamine oxidase inhibitors","volume":"19","author":"Chiuccariello","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF00442818","article-title":"Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines","volume":"99","author":"Fritze","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0091270010372105","article-title":"Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients","volume":"51","author":"Ignjatovic","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0924-977X(96)00023-5","article-title":"The role of cytochrome P450 2D6 in the metabolism of moclobemide","volume":"6","author":"H\u00e4rtter","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-3565(25)23665-5","article-title":"Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A","volume":"248","author":"Da Prada","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","article-title":"Tranylcypromine in mind (part I): review of pharmacology","volume":"27","author":"Ulrich","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.euroneuro.2013.01.002","article-title":"5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects","volume":"23","author":"Stenkrona","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1742-7843.2011.00810.x","article-title":"Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects","volume":"110","author":"Areberg","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.nucmedbio.2006.02.007","article-title":"The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites","volume":"33","author":"Zeng","year":"2006","journal-title":"Nucl Med Biol"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-2039-2829","article-title":"Low escitalopram concentrations in patients with depression predict treatment failure: a naturalistic retrospective study","volume":"56","author":"Hart","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00406-022-01491-9","article-title":"Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder","volume":"273","author":"Hart","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis","volume":"239","author":"Hart","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503","volume":"62","author":"Ishikawa","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","article-title":"Mechanisms of action of fluvoxamine for COVID-19: a historical review","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:09:45Z","timestamp":1748956185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001142","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"2023-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}